Exciting Developments in Ocular Health
Nicox SA is making significant strides in the field of ophthalmology, particularly with its exclusive Japanese partner, Kowa. They have recently announced that Kowa has received the necessary regulatory approval to start Phase 3 clinical trials for NCX 470, a novel treatment targeting ocular hypertension. This milestone marks a crucial step in bringing innovative solutions to patients in Japan.
Milestone Payments and Financial Stability
As part of this collaboration, Nicox is set to receive up to €3 million in milestone payments from Kowa in 2025. Specifically, an initial payment of €1 million will be made upon the commencement of the Phase 3 clinical trials. A second payment of €2 million is anticipated once these trials officially begin. These funds are expected to significantly enhance Nicox's financial runway, allowing operations to continue through at least the end of 2025.
Enhancing the Cash Runway
With the anticipated revenue from Kowa and other sources, Nicox has projected a sustained cash status that will support the company's ongoing endeavors in bringing NCX 470 to market. This financial backing is crucial, as it provides the necessary resources for research and development, particularly in navigating the complexities of clinical trials and regulatory processes.
Future Clinical Trial Milestones
Looking ahead, Nicox has set several key milestones that are expected to drive both progress and funding. The Denali Phase 3 clinical trial, which evaluates NCX 470's effectiveness in patients with open-angle glaucoma or ocular hypertension, is expected to yield topline results in the third quarter of 2025. Meanwhile, the Phase 3 clinical trial in Japan is set to commence in the second half of 2025.
Status of NCX 470
NCX 470 is Nicox’s leading clinical product candidate, designed to lower intraocular pressure. It represents a promising advancement in treating ocular conditions, with a focus on safety and efficacy. The company has successfully navigated prior phases, and the ongoing trials are poised to further substantiate its development path.
About Nicox: Pioneers in Ophthalmology
Nicox SA is dedicated to advancing ocular health through innovative solutions. Headquartered in Sophia Antipolis, France, the company focuses on developing groundbreaking treatments like NCX 470. Its portfolio also includes other notable projects and collaborative initiatives aimed at addressing various ocular conditions. As part of its research agenda, Nicox is also exploring NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, in collaboration with Glaukos.
Additionally, Nicox continues to capitalize on its first commercial product, VYZULTA®, currently available in the U.S. and over 15 other markets. This product, along with ZERVIATE®, underscores Nicox's commitment to improving patient outcomes in ocular health.
Contact Information for Nicox
For those seeking more information about Nicox and its products, Gavin Spencer, the Chief Executive Officer, is available for inquiries. He can be reached at T +33 (0)4 97 24 53 00 or via email at communications@nicox.com.
Frequently Asked Questions
What is NCX 470?
NCX 470 is Nicox's lead clinical candidate, a nitric oxide-donating bimatoprost eye drop developed to reduce intraocular pressure in patients with open-angle glaucoma.
When will the Phase 3 trials for NCX 470 begin in Japan?
The Phase 3 clinical trials in Japan are expected to start in the second half of 2025.
What financial benefits will Nicox receive from Kowa?
Nicox will receive up to €3 million in milestone payments from Kowa as the development progresses in Japan.
How does Nicox ensure financial stability?
With anticipated revenue from Kowa and continued research efforts, Nicox estimates it is financed until at least the end of 2025.
Where is Nicox headquartered?
Nicox is headquartered in Sophia Antipolis, France, and is listed on Euronext Growth Paris under the symbol ALCOX.
